Evotec AG (NASDAQ:EVO) Short Interest Down 68.3% in December

Evotec AG (NASDAQ:EVO) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 251,399 shares, a decline of 68.3% from the December 15th total of 793,290 shares. Based on an average trading volume of 341,984 shares, the short-interest ratio is presently 0.7 days. Approximately 0.1% of the shares of the stock are short sold. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 341,984 shares, the short-interest ratio is presently 0.7 days.

Hedge Funds Weigh In On Evotec

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE lifted its stake in Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the last quarter. UMB Bank n.a. purchased a new stake in shares of Evotec in the second quarter worth approximately $56,000. Valeo Financial Advisors LLC bought a new stake in shares of Evotec during the 2nd quarter worth approximately $43,000. WCM Investment Management LLC purchased a new position in Evotec during the 2nd quarter valued at $1,239,000. Finally, Envestnet Asset Management Inc. bought a new position in Evotec in the 2nd quarter valued at $385,000. Institutional investors own 5.81% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Evotec from a “sell” rating to a “hold” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.00.

Evotec Stock Down 4.4%

NASDAQ EVO traded down $0.17 during trading on Wednesday, hitting $3.70. 44,221 shares of the stock traded hands, compared to its average volume of 80,138. Evotec has a 12-month low of $2.84 and a 12-month high of $4.80. The firm has a 50-day simple moving average of $3.16 and a 200-day simple moving average of $3.61. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.03 and a current ratio of 2.12.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.